Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2019 Jan 16;20(1):6.
doi: 10.1186/s10194-018-0955-y.

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

Simona Sacco  1 , Lars Bendtsen  2 , Messoud Ashina  2 , Uwe Reuter  3 , Gisela Terwindt  4 , Dimos-Dimitrios Mitsikostas  5 , Paolo Martelletti  6
Affiliations
Practice Guideline

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

Simona Sacco et al. J Headache Pain. .

Erratum in

Abstract

Background and aim: Monoclonal antibodies acting on the calcitonin gene-related peptide or on its receptor are new drugs to prevent migraine. Four monoclonal antibodies have been developed: one targeting the calcitonin gene-related peptide receptor (erenumab) and three targeting the calcitonin gene-related peptide (eptinezumab, fremanezumab, and galcanezumab). The aim of this document by the European Headache Federation (EHF) is to provide an evidence-based and expert-based guideline on the use of the monoclonal antibodies acting on the calcitonin gene-related peptide for migraine prevention.

Methods: The guideline was developed following the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) approach. The working group identified relevant questions, performed systematic review and analysis of the literature, assessed the quality of available evidence, and wrote recommendations. Where the GRADE approach was not applicable, expert opinion was provided.

Results: We found low to high quality of evidence to recommend eptinezumab, erenumab, fremanezumab, and galcanezumab in patients with episodic migraine and medium to high quality of evidence to recommend erenumab, fremanezumab, and galcanezumab in patients with chronic migraine. For several clinical questions, there was not enough evidence to provide recommendations using the GRADE approach and recommendations relied on experts' opinion.

Conclusion: Monoclonal antibodies acting on the calcitonin gene-related peptide are new drugs which can be recommended for migraine prevention. Real life data will be useful to improve the use of those drugs in clinical practice.

Keywords: Calcitonin gene-related peptide; Chronic migraine; Eptinezumab; Erenumab; Fremanezumab; Galcazenumab; Migraine; Prevention.

PubMed Disclaimer

Conflict of interest statement

Authors, Financial disclosure (consulting, speaking fees, travel grants, research support). Simona Sacco Allergan, Bayer Healthcare, Eli Lilly, Medtronic, Novartis, TEVA. Lars Bendtsen Allergan, Biogen, Novartis, Teva. Messoud Ashina Allergan, Alder, Amgen, Eli Lilly, Novartis, Teva. Dimos-Dimitrios Mitsikostas Allergan, Amgen, Cefaly, ElectroCore, Genesis Pharma, Eli Lilly, Merck-Serono, Novartis, Roche, Sanofi-Genzyme, Speficar, Teva. Uwe Reuter Amgen, Autonomic Technologies Eli Lilly, Novartis, Teva. Gisela Terwindt Eli Lilly, Novartis, Teva. Paolo Martelletti Allergan, Amgen, Electrocore, Eli Lilly, Novartis, Springer HealthCare, Teva.

Figures

Fig. 1
Fig. 1
Process of identifying eligible studies for the guideline
Fig. 2
Fig. 2
Risk of bias summary for the studies considered for the guideline
See this image and copyright information in PMC

Comment in

References

    1. GBD 2015 Disease and injury incidence and prevalence collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–1602. doi: 10.1016/S0140-6736(16)31678-6. - DOI - PMC - PubMed
    1. Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight project. J Headache Pain. 2010;11:289–299. doi: 10.1007/s10194-010-0217-0. - DOI - PMC - PubMed
    1. Victor T, Hu X, Campbell J, Buse D, Lipton R. Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia. 2010;30:1065–1072. doi: 10.1177/0333102409355601. - DOI - PubMed
    1. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population - burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71:559–566. doi: 10.1212/01.wnl.0000323925.29520.e7. - DOI - PubMed
    1. Friedman AP, Losin S. Evaluation of UML-491 in the treatment of vascular headaches. An analysis of the effects of 1-methyl-D-lysergic acid (plus) butanolamide bimaleate (methysergide) Arch Neurol. 1961;4:241–245. doi: 10.1001/archneur.1961.00450090007002. - DOI - PubMed

Publication types

MeSH terms